GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

Pharmaceutical titan GSK has witnessed a profit tumble owing to charges linked with the litigation over Zantac, yet has reiterated its financial forecasts, stressing stability in the company's core ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. The objectives were to (i) synthesize and characterize a series ...

Around £2billion was added to the value of GSK after the pharmaceuticals giant agreed a £1.7billion settlement over claims that its heartburn medicine Zantac caused cancer. Shares rose 3.2 per ...

GSK agreed to pay $2.2 billion to settle approximately 80,000 lawsuits in U.S. courts over claims its heartburn drug, Zantac, caused cancer. The settlements account for 93% of all cases and were ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Zantac, first sold in the US in 1983, was one of the best-selling medicines globally, bringing in more than $1bn (€0.91bn) in sales per year. It was also sold by Sanofi, a French drug company ...